Next Article in Journal
Food for Bone: Evidence for a Role for Delta-Tocotrienol in the Physiological Control of Osteoblast Migration
Next Article in Special Issue
Pharmacogenomics of Hypertension Treatment
Previous Article in Journal
Investigation of Cytotoxic T Lymphocyte Function during Allorejection in the Anterior Chamber of the Eye
Previous Article in Special Issue
DRUGPATH: The Drug Gene Pathway Meta-Database
Review

Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact

IRCCS Istituto Ortopedico Rizzoli, Laboratory of Experimental Oncology, Pharmacogenomics and Pharmacogenetics Research Unit, 40136 Bologna, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(13), 4659; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21134659
Received: 28 May 2020 / Revised: 23 June 2020 / Accepted: 25 June 2020 / Published: 30 June 2020
(This article belongs to the Special Issue Pharmacogenomics)
High-grade osteosarcoma (HGOS) is a very aggressive bone tumor which primarily affects adolescents and young adults. Although not advanced as is the case for other cancers, pharmacogenetic and pharmacogenomic studies applied to HGOS have been providing hope for an improved understanding of the biology and the identification of genetic biomarkers, which may impact on clinical care management. Recent developments of pharmacogenetics and pharmacogenomics in HGOS are expected to: i) highlight genetic events that trigger oncogenesis or which may act as drivers of disease; ii) validate research models that best predict clinical behavior; and iii) indicate genetic biomarkers associated with clinical outcome (in terms of treatment response, survival probability and susceptibility to chemotherapy-related toxicities). The generated body of information may be translated to clinical settings, in order to improve both effectiveness and safety of conventional chemotherapy trials as well as to indicate new tailored treatment strategies. Here, we review and summarize the current scientific evidence for each of the aforementioned issues in view of possible clinical applications. View Full-Text
Keywords: osteosarcoma; pharmacogenomics; pharmacogenetics; toxicity; tailored treatment osteosarcoma; pharmacogenomics; pharmacogenetics; toxicity; tailored treatment
Show Figures

Graphical abstract

MDPI and ACS Style

Hattinger, C.M.; Patrizio, M.P.; Luppi, S.; Serra, M. Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact. Int. J. Mol. Sci. 2020, 21, 4659. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21134659

AMA Style

Hattinger CM, Patrizio MP, Luppi S, Serra M. Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact. International Journal of Molecular Sciences. 2020; 21(13):4659. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21134659

Chicago/Turabian Style

Hattinger, Claudia M., Maria P. Patrizio, Silvia Luppi, and Massimo Serra. 2020. "Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact" International Journal of Molecular Sciences 21, no. 13: 4659. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21134659

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop